Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of your participation in this study is to help answer the following
research question: Whether 12-week administration of EMSAM (selegiline transdermal system) is
safe and effective for the treatment of adolescents (aged 12 through 17 years) with Major
Depressive Disorder (MDD).